Company
BioVaxys Technology Corp.
CNSX:BIOV
Based in Vancouver, BioVaxys Technology Corp. is a British Columbia-registered, early-stage biotechnology company that is developing viral and oncology vaccine platforms, as well as immuno-diagnostics. The company is advancing a SARS-CoV-2 vaccine based on its haptenized viral protein technology, and is planning a clinical trial of its haptenized autologous cell vaccine used in combination with anti-PD1 and anti-PDL-1 checkpoint inhibitors that will initially be developed for ovarian cancer. Also in development is a diagnostic for evaluating the presence or absence of a T cell immune response to SARS-CoV-2, the virus that causes COVID-19. BioVaxys has two issued US patents and two patent applications related to its cancer vaccine, and pending patent applications for its SARS-CoV-2 (Covid-19) vaccine and diagnostic technologies.
39 stories · page 1 of 2
BioVaxys Technology closes first tranche of non-brokered private placement for total gross proceeds of $117,500
The company said it intends to use the net proceeds of the private placement for working capital purposes
BioVaxys says initial results from study into universal vaccine against Covid-19 virus family are promising
COO Kenneth Kovan said the interim data supports the development of a safe and well-tolerated solution for sarbecoviruses
BioVaxys Technology signs exclusive distribution deal for cervical lesion treatments from Spain-based Procare Health
The products are Paplicocare, a vaginal gel to prevent and treat HPV-dependent cervical lesions, and Immunocaps, an oral over-the-counter nutritional supplement that supports immune function and vaginal microbiota to help re-epithelializati
BioVaxys Technology files international patent application for its SARS1 vaccine
The action further expands the value of its intellectual property (IP) portfolio, the company said
BioVaxys Technology adds experienced CFO Craig Loverock to its executive team
Loverock brings more than 25 years of accounting and financial management experience in Canada, the US and the UK to the company
BioVaxys Technology announces completed synthesis of its pan-sarbecovirus vaccine candidate and launch of in vivo animal study
BioVaxys president Kenneth Kovan said: "Barring any unforeseen circumstances, we anticipate data from the study in September"
Biovaxys Technology says its French collaborator has excised the first tumors to produce 'dry runs' of its ovarian cancer vaccine
The so-called dry runs an important part of completing the standardized Good Manufacturing Process
BioVaxys says bio-manufacturing partner BioElpida completes next phase of BVX-0918 production for EU Clinical study
"Completion of OVCAR-3 cell banks is another step towards our ability to produce GMP yields of BVX-0918, and brings us closer to our Phase I study in the EU planned for later this year," said BioVaxys president and COO Kenneth Kovan
BioVaxys Technology and Ohio State University reach milestone in joint research evaluating the company's "universal vaccine" for sarbecoviruses
The next step will be immunizing the test animals with BVX-1021, BioVaxys' "booster" vaccine to be administered with current SARS-CoV-2 vaccines, to target sarbecoviruses
BioVaxys confirms first clinical site for Phase I ovarian cancer vaccine trial in France
The study on BVX-0918, the company's autologous haptenized tumor cell vaccine for late-stage ovarian cancer, will take place at Hospices Civils de Lyon in France
BioVaxys files to expand international cervical cancer vaccine patent protection
The biotechnology company said the application would grant BioVaxys' platform broad geographic market coverage outside the US for cervical cancer
BioVaxys enters critical tumor cell supply agreement with Deaconess Research Institute for BVX-0918 bioproduction
The company said the tumor cells will be used for process testing and manufacturing "dry runs" of BVX-0918, a major step leading to the completion of Good Manufacturing Process (GMP) production, a requirement for the planned Clinical Trial
BioVaxys Technology to expand cancer vaccine platform with investigator-sponsored trial of colorectal cancer therapy
Colorectal cancer is the third most common malignancy and the second most deadly cancer worldwide, with an estimated 1.9 million new cases diagnosed and 0.9 million deaths globally in 2020
BioVaxys announces bioproduction of BVX-1021 for its pan-sarbecovirus vaccine program with Ohio State University
The biotech has struck a deal with Millipore-Sigma to manufacture BVX-1021, its newly developed vaccine for the strain of coronavirus that causes severe acute respiratory syndrome (SARS1)